Health Trials

About this trial

The objective of the NeoPlaTT trial is to test whether, among extremely preterm infants born at 23 0/7 to 26 6/7 weeks' gestation, a lower platelet transfusion threshold, compared to a higher threshold, improves survival without major or severe bleeding up to 40 0/7 weeks' postmenstrual age (PMA).

Eligibility criteria

Qualifiers

Gestational age of 23 0/7 to 26 6/7 weeks

Postnatal age of < 48 hours

Disqualifiers

Comfort care or withdrawal of care planned

Neonatal alloimmune thrombocytopenia or suspected/confirmed congenital platelet or bleeding disorder

Receipt of platelet transfusion

No receipt of Vitamin K

Trial design

Treatments tested in this trial

  • Higher Platelet Transfusion Threshold
  • Lower Platelet Transfusion Threshold

Treatment groups

2,433 Participants
are divided into 2 treatment groups

Locations

20
Alabama
University of Alabama at Birmingham35233, Birmingham United States
California
Stanford University94304, Palo Alto United States
Sharp Mary Birch Hospital for Women & Newborns92123, San Diego United States
Colorado
University of Colorado80045, Aurora United States

Sponsors and collaborators

NICHD Neonatal Research Network

Lead sponsor

National Heart, Lung, and Blood Institute (NHLBI)

Collaborator

Source ClinicalTrials.gov